AzTrials
AzTrials

Induction of LaborNCT06335017

Castor Oil Ingestion and Balloon Catheter for Labor Induction in Multiparous

A study testing Induction of labor in people with Induction of Labor, run by Holy Family Hospital, Nazareth, Israel at 1 site in Israel.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this randomized controlled trial is to examine the efficacy of combining castor oil ingestion with extra-amniotic single balloon catheter for cervical ripening on time from induction to delivery in multiparous women. Read more about this study

Who is it for?
Ages 18 to 60 years, women onlyHealthy volunteers can take part
Conditions the study is for
Induction of Labor
What is being tested?
Induction of labor
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
216 participants
Where
1 siteIsrael
Study dates
10 Apr 2024to Dec 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Women above 18 years old
  • Sign an informed consent
  • Term pregnancy (>37 weeks)
  • Viable fetus
  • Singleton
  • Vertex presentation
  • Intact membranes
  • Cervix with Bishop score ≤6

Who cannot join

  • Previous cesarean delivery
  • Major fetal malformations
  • Contraindication to spontaneous vaginal delivery
  • Amniotic fluid index >25cm
  • Chorioamnionitis at admission
  • Placental abruption
Show all 11Show fewer
  • Previous prostaglandin use for induction of labor
  • A low-lying placenta (up to 2 cm from the internal os)
  • Carriers of hepatitis B or C or human immunodeficiency viruses,
  • Women with a history of allergy to latex.
  • Women with a history of allergy to castor oil

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Israel1 site, 1 recruiting
  • Holy Family hospital, Nazareth

    Nazareth

    Wiaam Khatib, MD, 0549192433, wiaam.khatib.95@gmail.com

    Raed Salim, MD, r.salim@hfhosp.org

    Recruiting

Other trials in Israel

About this study

Official title: The Effect of Combining Balloon Catheter With Castor Oil Ingestion for Cervical Ripening on Time to Delivery Among Multiparous Women.

The goal of this randomized controlled trial is to examine the efficacy of combining castor oil ingestion with extra-amniotic single balloon catheter for cervical ripening on time from induction to delivery in multiparous women.

The main question it aims to answer are:

Read more

Does the addition of the use of castor oil to extra-amniotic single balloon reduce the time until birth? Does the addition of the castor oil affect other perinatal outcomes during childbirth? Are the side effects of the castor tolerated by the mothers? Participants will be randomly divided into 2 groups: the study group will drink a mixture of 60 ml of castor oil mixed with 140 ml of orange juice. Thirty minutes later, extra-amniotic single balloon catheter will be inserted above the internal cervical os and filled with 60 mL of normal saline.

In the control group, the catheter will be inserted into cervical canal without ingestion of castor oil.

Read the detailed description

The rate of labor induction has increased up to 25.7% in 2018 for several demographic and obstetric reasons.

Various methods are used to induce labor worldwide, including natural, mechanical and pharmacological agents. of all methods balloon catheters were proven to cause fewer adverse perinatal events.

Though induction is considered a safe and effective procedure, it may lead to a prolonged labor which is associated with complications such postpartum hemorrhage, infection, and operative delivery.

Based on these data several studies have examined the combinations of balloon catheters with other pharmacological agents on labor durations. The results were inconsistent, and several reports showed that the combination reduced significantly the length of labor. Nevertheless, pharmacological agents may be associated with adverse events including uterine hyperstimulation, placental abruption, and postpartum hemorrhage, though the overall risk is small.

Castor oil, extracted from the seeds of Ricinus communis plant, is a natural effective substance for induction of labor. it's considered a safe and inexpensive though the exact mechanism by which it induces labor is still unclear.

Our hypothesis suggests that ingestion of castor oil combined with the balloon catheter will shorten the time to delivery. In order to show a reduction by 2 hours, a sample size of 98 in each group will be needed assuming 80% power and a two-tailed alpha of 5%. Since the success rate of vaginal delivery was nearly 95% according to the same report, the sample size was calculated to 103 women in each group. Additional 5% are planned to be recruited to account for trial drop out for any reason, yielding a total final sample size of 108 women in each group (216 in both groups).

Being tested
Induction of labor

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Induction of laborDietary supplement

    In both groups the balloon catheter will be removed at nearly 12 hours after insertion. Following removal, artificial rupture of the membranes will be performed as long as it is safe with regards to fetal head position. Oxytocin infusion will be commenced at once if contraction has not begun spontaneously (2 to 3 regular uterine contractions per 10 minutes). Continuous electronic fetal monitoring will be used throughout labor. Labor will be managed by the attending obstetricians and midwives. Labor progress abnormalities will be diagnosed and managed according to the department protocol based on the recommendations of the American College of Obstetricians and Gynecologists.

Study groups in NCT06335017
Study groupRoleWhat they receive
group 1 - study groupActive comparatorCandidates will drink a mixture of 60 ml of castor oil and 140 ml of orange juice. 30 minutes later, A 22-French Foley catheter will be inserted above internal cervical os and will be filled with 60 mL of normal saline.
Receives: Dietary Supplement: Induction of labor
group 2- controlActive comparatorA foley catheter will be inserted into cervical canal as described above according to the department protocol without ingestion of castor oil.
Receives: Dietary Supplement: Induction of labor

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. time to delivery

    Time from catheter insertion to vaginal delivery

    Measured: 48 hours

Secondary outcomes (32)
  1. balloon expulsion time

    The time until balloon was spontaneously expelled

    Measured: 12 hours after insertion

  2. Bishop score at catheter expulsion

    Bishop score after removal of the catheter where a high score (above 7) indicates a better outcome

    Measured: 12 hours

  3. Number of women that will have non-vertex presentation after removal of the catheter

    The insertion of a balloon may lead to a change in the presenting part of the fetus. A change to a non-vertex presentation is carried as an undesired outcome.

    Measured: 48 hours

  4. Duration of active phase

    Duration of the time from 6 cm cervical dilatation to 10 cm cervical dilatation

    Measured: 4 hours

  5. Duration of second stage

    the time from 10 cm cervical dilatation until the delivery of the baby

    Measured: 4 hours

  6. Mode of delivery

    Whether the birth was a normal spontaneous birth, operative vaginal birth or a cesarean section

    Measured: 48 hours

  7. Indications for cesarean or vacuum deliveries

    Was the reason for operative vaginal delivery or cesarean delivery due to non progress labor, fetal status, or a combination of both?

    Measured: 48 hours

  8. Number of patients that will have intrapartum fever ≥ 38 °C

    Intrapartum fever ≥ 38 °C

    Measured: 48 hours

  9. Number of patients that will require use of intrapartum use of antibiotic treatment

    Number of patients that will require use of intrapartum use of antibiotic treatment due to intrapartum infection.

    Measured: 48 hours

  10. Number of Participants with that will develop clinical signs of chorioamnionitis.

    Clinical signs of chorioamnionitis includes abdominal tenderness, abnormal discharge, intrapartum fever, and tachycardia

    Measured: 48 hours

  11. Number of Participants with that will develop 3rd and 4th degrees perineal lacerations.

    Obstetric anal sphincter injury

    Measured: 48 hours

  12. Number of Participants with develop postpartum hemorrhage.

    early postpartum hemorrhage (PPH)

    Measured: 48 hours

  13. Number of Participants with need blood transfusion.

    PPH that will require blood transfusion.

    Measured: 72 hours

  14. Number of women that will have side effects related to castor oil use

    nausea, vomiting, uterine hyperstimulation> the 5 contractions: 10 minutes

    Measured: 48 hours

  15. Oxytocin dosage

    A higher oxytocin dosage indicates lesser outcome.

    Measured: 48 hours

  16. Number of participants with Umbilical Cord prolapse.

    Umbilical cord prolapse is when the umbilical cord exits the cervical os before the fetal presenting part that may result in fetal hypoxia.

    Measured: 48 hours

  17. Number of neonates that will have Apgar score (range 0 to 10) <7.

    APGAR< 7 after 1 and 5 minutes where lower scores mean a worse outcome.

    Measured: 48 hours

  18. number of women with cord artery pH <7.1

    pH taken from umbilical artery (lower pH means worse outcome)

    Measured: 48 hours

  19. Neonatal birthweight

    Neonatal birthweight

    Measured: 48 hours

  20. Number of neonates with Neonatal fever ≥ 38 °C

    Neonatal fever > 38 °C

    Measured: 72 hours

  21. The number of neonates that will develop neonatal sepsis.

    Diagnosis of neonatal sepsis based on clinical signs of sepsis and positive cultures.

    Measured: 72 hours

  22. The number of neonates that will require antibiotic treatment.

    Need for antibiotic treatment

    Measured: 72 hours

  23. number of neonates with any neonatal complications

    respiratory distress syndrome, transient tachypnea of newborn, intracranial hemorrhage, intraventricular hemorrhage, seizures, Meconium aspiration syndrome ,Hypoxic ischemic encephalopathy

    Measured: 48 hours

  24. The number of neonates that will Admit to neonatal intensive care unit (NICU)

    Neonatal admission to NICU

    Measured: 30 days

  25. Length of stay in NICU.

    Neonatal length of stay in NICU

    Measured: 30 days

  26. Number of neonatal death

    neonatal death

    Measured: 30 days

  27. Maternal hemoglobin level after delivery.

    higher level of Hemoglobin indicates better outcome.

    Measured: 48 hours

  28. Number of participants that will require postpartum hysterectomy.

    Maternal hysterectomy

    Measured: 72 hours following delivery

  29. Number of participants that will require postpartum laparotomy.

    Number of participants that will require postpartum laparotomy after vaginal delivery or re-laparotomy after cesarean section.

    Measured: 72 hours following delivery.

  30. Number of women that will develop postpartum complications

    endometritis

    Measured: 72 hours following the delivery.

  31. The length of stay from birth to discharge home.

    The length of stay in days from birth to discharge home.

    Measured: up to 10 days

  32. Maternal satisfaction

    1 = Very dissatisfied, 10 = Very satisfied

    Measured: up to 10 days after delivery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Mar 2024
  2. Study start10 Apr 2024
  3. Primary completionNov 2026 (estimated)
  4. Study completionDec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
216 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06335017
Sponsor's protocol ID
294-2024-HFH
Status last verified
Apr 2026
First submitted
5 Mar 2024
Last updated
13 Apr 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: IPD that underlie results in a publication

Questions about this trial

What is this clinical trial studying?

A study testing Induction of labor in people with Induction of Labor, run by Holy Family Hospital, Nazareth, Israel at 1 site in Israel.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 13 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Raed Salim, MD (: +972544986960, r.salim@hfhosp.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

time to delivery (time frame: 48 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in